• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    6/9/26 6:02:06 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous
    Get the next $NOVT alert in real time by email
    8-K
    0001076930false00010769302026-06-082026-06-080001076930novt:SixPointFiveZeroPercentTangibleEquityUnitsMember2026-06-082026-06-080001076930us-gaap:CommonStockMember2026-06-082026-06-08

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 8, 2026

    NOVANTA INC.

    (Exact name of registrant as specified in is charter)

     

    New Brunswick, Canada

    001-35083

    98-0110412

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    125 Middlesex Turnpike

    Bedford, Massachusetts

    01730

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: (781) 266-5700

    Not Applicable

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common shares, no par value

     

    NOVT

     

    Nasdaq Global Select Market

    6.50% Tangible Equity Units

     

    NOVTU

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

    Item 1.01 Entry into a Material Definitive Agreement.

    Equity Purchase Agreement

    On June 8, 2026, Novanta Inc., a Canadian corporation (the “Company”), Novanta Medical Technologies Corp., a Delaware corporation and an indirect subsidiary of the Company (“Buyer”), Novanta Corporation, a Michigan corporation (“Intermediate Parent”, and together with the Company and the Buyer, the “Buyer Parties”), Runway Midco, LLC, a Delaware limited liability company (“Seller”), and Runway Buyer, LLC, a Delaware limited liability company and direct wholly owned subsidiary of Seller (“Runway Buyer”), entered into an Equity Purchase Agreement (the “Purchase Agreement”), pursuant to which Buyer will acquire from Seller all of the issued and outstanding limited liability company interests (the “Purchased Interests”) of Runway Buyer (the “Transaction”).

    Transaction Consideration

    Subject to the terms and conditions of the Purchase Agreement, at the closing of the Transaction (the “Closing”), the Buyer Parties will pay Seller $1,200,000,000 in cash (the “Closing Consideration”). In addition, a milestone payment amount of $250,000,000 is payable by the Buyer Parties to Seller on or before January 8, 2027. The Closing Consideration is subject to customary adjustments based on cash, working capital, debt and transaction expenses of Runway Buyer as of the Closing.

    Conditions to the Transaction

    The Closing is subject to satisfaction or waiver of certain conditions, including, among other things, (a) the absence of any law, order or injunction by any governmental entity of competent jurisdiction preventing the completion of the Transaction or making the completion of the Transaction illegal, (b) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), without the imposition of an unacceptable condition, (c) subject to certain exceptions, the accuracy of representations and warranties with respect to the Buyer Parties, Runway Buyer and the Seller, (d) compliance in all material respects by the Buyer Parties, Runway Buyer and the Seller with their respective covenants contained in the Purchase Agreement and (e) the absence of any Material Adverse Effect (as defined in the Purchase Agreement) with respect to Runway Buyer.

    Financing of the Transaction

    The Transaction will be financed through a combination of cash on hand, the Company’s existing credit facilities available under the Credit Agreement (as defined below) and proceeds from the Company’s equity issuance announced today.

    In connection with the Transaction, Intermediate Parent, the Company, and certain wholly-owned subsidiaries of the Company entered into the Third Amendment to Fourth Amended and Restated Credit Agreement (the “Third Amendment”), with Bank of America, N.A., as administrative agent and lender, and the other lenders party thereto, which amends that certain Fourth Amended and Restated Credit Agreement dated as of June 27, 2025 (as amended, the “Credit Agreement”).

    The Third Amendment, among other things, amends (i) the interest rate applicable to loans under the Credit Agreement by widening the pricing margin by 0.25% if the Company’s consolidated leverage ratio exceeds 3.75 to 1.00 and (ii) amends the financial covenants under the Credit Agreement by (x) increasing the permitted consolidated leverage ratio to 4:00 to 1.00 or 4.50 to 1.00 for four consecutive quarters following a Designated Acquisition (as defined in the Credit Agreement) and (y) decreasing the permitted consolidated fixed charge coverage ratio to 1.00 to 1.00 for the four consecutive fiscal quarters following consummation of the Transaction.

    The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Third Amendment, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

    Certain Other Terms of the Purchase Agreement

    The Purchase Agreement contains customary representations, warranties and covenants made by the Buyer Parties, Runway Buyer and Seller, including covenants relating to the conduct of Runway Buyer’s business between the date of signing the Purchase Agreement and the Closing, regulatory approvals, access to information, employee matters, confidentiality and exclusivity. The Buyer Parties will obtain a representations and warranties insurance policy in connection with the Transaction. The Company and Intermediate Parent will guarantee the prompt payment and performance of all present and future payment and performance obligations of Buyer to Seller and Runway Buyer under the Purchase Agreement and the other transaction documents.

    The Purchase Agreement contains certain customary termination rights, including, among others, (i) the right of either Buyer or Seller to terminate by mutual written agreement, (ii) the right of either Buyer or Seller to terminate if the Transaction has not been consummated within one hundred fifty (150) days after the date of the Purchase Agreement, (iii) the right of either Buyer or Seller to terminate if a governmental authority has issued any final, non-appealable order that has the effect of permanently restraining,

     


     

    enjoining or otherwise prohibiting the Transaction, (iv) the right of either Buyer or Seller to terminate due to a material breach by the other party of any of its representations, warranties or covenants which would result in the closing conditions not being satisfied, subject to certain conditions, and (v) the right of Seller or Buyer to terminate if Closing is not timely consummated (subject to a notice period for Buyer).

    The foregoing summary does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is attached hereto as Exhibit 2.1 and is incorporated herein by reference.

    The Purchase Agreement has been attached as an exhibit to this Current Report on Form 8-K in order to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company, Runway Buyer, Seller or their respective affiliates or to modify or supplement any factual disclosures about the Company, Runway Buyer, Seller or their respective affiliates in public reports filed with the SEC. The Purchase Agreement includes representations, warranties and covenants of the Buyer Parties, Runway Buyer and Seller that were made solely for the purposes of the Purchase Agreement and as of specific dates, were solely for the benefit of the parties thereto, and which may be subject to important qualifications and limitations agreed to by the Buyer Parties, Runway Buyer and Seller in connection with the negotiated terms of the Purchase Agreement. Moreover, such representations and warranties may not be accurate or complete as of any specified date, have been modified or qualified by certain disclosures between the parties made in connection with the negotiation of the Purchase Agreement, which disclosures are not reflected in the Purchase Agreement itself, and may apply contractual standards of materiality in a way that is different from that which may be viewed as material by the Company’s stockholders or other security holders. In addition, the representations and warranties were made for purposes of allocating risk among the parties to the Purchase Agreement and were not intended, and should not be relied upon, as statements of fact. Information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

    Item 7.01 Regulation FD Disclosure.

    On June 9, 2026, the Company issued a press release announcing the Transaction. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

    Also on June 9, 2026, the Company will hold a conference call to discuss the Transaction. A copy of the conference call presentation is attached hereto as Exhibit 99.2 and is also available on the Company’s website, https://www.novanta.com, in the Investor section.

    Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

    Cautionary Note Regarding Forward-Looking Statements

    Certain statements in this Current Report on Form 8-K are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “will,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, the expected timing and completion of the transaction, the ability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner, the anticipated benefits and synergies of the transaction, the expected financing of the transaction statements, and other statements that are not historical facts.

    These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause future expectations and actions and actual results to differ materially from those contained in the forward-looking statements. Our future expectations and actions and actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: the risk that the transaction may not be completed on the anticipated timeline or at all; the possibility that any of the anticipated benefits or synergies of the transaction may not be realized; the risk that the business of Runway Buyer and its subsidiaries may not be integrated successfully; risks relating to the financing for the transaction; risks relating to the effect of the announcement of the proposed transaction on the ability of Runway Buyer and its subsidiaries to retain and hire key personnel and maintain relationships with its key business partners and customers, and others with whom it does business, or on its operating results and businesses generally; risks associated with the disruption of our, Runway Buyer and its subsidiaries’ management’s attention from ongoing business operations due to the proposed transaction; the significant costs associated with the proposed transaction; and other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition that are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently

     


     

    available to the Company. Undue reliance should not be placed on these statements, which are only effective as of the date of this Current Report on Form 8-K. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this Current Report on Form 8-K except as required by law.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

     2.1*

     

    Equity Purchase Agreement, dated as of June 8, 2026, by and among Novanta Medical Technologies Corp., Novanta Corporation, Novanta Inc., Runway Midco, LLC and Runway Buyer, LLC

     10.1

     

    Third Amendment to Fourth Amended and Restated Credit Agreement, dated as of June 8, 2026

     99.1

     

    Press Release issued June 9, 2026 by the Company

     99.2

     

    Investor Conference Call Presentation issued June 9, 2026

     104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    * All schedules and exhibits to the Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Novanta Inc.

    Date: June 9, 2026

    By:

    /s/ Robert J. Buckley

    Robert J. Buckley

    Chief Financial Officer

     

     

     

     


    Get the next $NOVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOVT

    DatePrice TargetRatingAnalyst
    3/30/2026$144.00Neutral → Outperform
    Robert W. Baird
    5/11/2022Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $NOVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Glastra Matthijs sold $1,096,273 worth of shares (6,500 units at $168.66) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 36,261 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    6/4/26 4:05:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Glastra Matthijs sold $1,128,244 worth of shares (7,500 units at $150.43) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 42,761 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    5/14/26 4:06:13 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Glastra Matthijs sold $852,348 worth of shares (6,500 units at $131.13) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 50,261 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    5/7/26 4:16:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation

    6/22/26 5:00:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces $300 Million Private Placement

    Novanta Inc. ("Novanta" or the "Company") announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares ("Common Shares") to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions. The offer and s

    6/9/26 6:15:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces Acquisition of Riverpoint Medical

    Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from

    6/9/26 6:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    SEC Filings

    View All

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - NOVANTA INC (0001076930) (Filer)

    6/9/26 5:00:16 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOVANTA INC (0001076930) (Filer)

    6/9/26 6:02:06 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - NOVANTA INC (0001076930) (Filer)

    5/29/26 4:45:15 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novanta upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Novanta from Neutral to Outperform and set a new price target of $144.00

    3/30/26 8:13:23 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta upgraded by William Blair

    William Blair upgraded Novanta from Mkt Perform to Outperform

    5/11/22 6:19:56 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Financials

    Live finance-specific insights

    View All

    Novanta Inc. Announces Acquisition of Riverpoint Medical

    Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from

    6/9/26 6:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Announces Financial Results for the First Quarter 2026

    First Quarter 2026 GAAP Revenue increased 10% to $258 million First Quarter 2026 GAAP Net Income was $21 million, and Adjusted EBITDA increased 14% to $57 million First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026. Financial Highlights Three Months Ended   (In millions, except per share amounts) April 3,     March 28,     2026     2025  

    5/11/26 4:45:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 results after the close of U.S. financial markets on Monday, May 11, 2026. The Company will host a conference call on Tuesday, May 12, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hou

    4/14/26 11:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novanta Inc.

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    11/14/24 1:22:36 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Novanta Inc.

    SC 13G - NOVANTA INC (0001076930) (Subject)

    2/14/24 10:02:59 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G/A filed by Novanta Inc. (Amendment)

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    2/13/24 5:09:44 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Leadership Updates

    Live Leadership Updates

    View All

    IDEX Corporation Appoints Stephanie Disher and Matthijs Glastra to Board of Directors; David Parry and Livingston Satterthwaite to Retire

    IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

    2/20/25 5:07:00 PM ET
    $ATMU
    $IEX
    $NOVT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Fluid Controls
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care